Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions — Duke OTC
Aerie Pharmaceuticals gets $88M upfront in licensing agreement with Santen - Triangle Business Journal
ESCRS - Aerie in Europe
Aerie Pharmaceuticals Inc - Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of
Aerie Pharmaceuticals, Inc.
Santen Expands License Agreement with Aerie for Rhopressa and Rocklatan | Market Scope
Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% | Business Wire
Aerie Plots Next Steps with Rhopressa
Glaucoma Physician - February 12, 2021
Rhopressa enrolled in second Phase 3 registration trial
Alcon to buy Aerie Pharmaceuticals for $770M - News - MM+M
Aerie Pharmaceuticals Inc - Disclaimer The information in this presentation regarding Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) does not contain all of the information that a potential investor should review before
EX-99.1
Aerie Pharmaceuticals Inc - For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares.
Aerie Pharmaceuticals Announces Agreement to Acquire Avizorex Pharma to Advance Its Dry Eye Program | World Pharma Today
Aerie Pharmaceuticals, Inc. (Aerie Pharmace) Stock Price & News | AERI
Aerie Pharmaceuticals CEO discusses what's new in the pipeline
Aerie Pharmaceuticals, Inc. — Duke OTC
Articles about Aerie Pharmaceuticals, Inc. | page 4
Aerie Pharmaceuticals Inc - For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares.
Commercial Model Design And Execution EXEEVO • UBIQ
Articles about Aerie Pharmaceuticals, Inc. | page 5
Aerie Pharmaceuticals Inc - Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of
Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease | Business Wire
EX-99.1
Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% | Business Wire
Aerie Pharmaceuticals (Nasdaq: AERI) cleared to begin clinical testing for dry eye treatment - Triangle Business Journal
Aerie launches Ph3 trial for Roclatan eye drug in Europe - Drug Delivery Business
